Bliss GVS Pharmaceuticals Surges 20% as Anupam Rasayan Secures Up to 43% Stake for Rs 1,369 Crore
Bliss GVS Pharma Shares Surge 20 Percent as Anupam Rasayan India Announces Acquisition Plans
Bliss GVS Pharma shares reached a 20 percent upper circuit on Tuesday, marking a significant milestone for the company. The stock was trading at Rs 381.05 during the session, a substantial increase from its previous value.
The acquisition plans were announced by specialty chemicals firm Anupam Rasayan India, which has proposed to acquire up to 43.3 percent stake in Bliss GVS Pharma for Rs 1,369.51 crore. According to an exchange filing, Anupam Rasayan India will acquire the stake at Rs 299 per share, while also launching a mandatory open offer to purchase an additional 26 percent stake from public shareholders at the same price.
The acquisition will be funded through a Rs 300 crore term loan, with the remaining amount raised through a non-controlling, non-voting equity instrument. Anupam Rasayan India Managing Director Anand Desai stated that the company has entered into a definitive agreement for the transaction.
Read also: Treasury Yields Experience Largest Increase in Two Weeks Following Release of Labor Market Data
The deal is expected to strengthen Anupam Rasayan India's presence across the pharmaceutical value chain, from key starting materials to finished dosage formulations. Bliss GVS Pharma, listed on the NSE and BSE, is engaged in the development and export of formulations, including suppositories, tablets, capsules, and injectables.
With a portfolio of over 150 branded formulations, Bliss GVS Pharma is among the country's large manufacturers of suppositories and pessaries. The company operates manufacturing facilities in Maharashtra and Daman, with approvals from the USFDA and the World Health Organization. Anupam Rasayan India has stated that the combined platform will create an integrated pharmaceutical manufacturing chain with deeper backward integration and wider reach in regulated markets, including Europe and the United States.
Anupam Rasayan India Ltd reported a 40 percent rise in consolidated net profit at Rs 222.19 crore for 2025-26, compared to Rs 159.9 crore in the previous year. The acquisition is expected to further boost the company's financial performance.
| Company | Consolidated Net Profit (2025-26) | Consolidated Net Profit (Previous Year) | % Change |
|---|---|---|---|
| Anupam Rasayan India Ltd | Rs 222.19 crore | Rs 159.9 crore | 40% |
Read also: US-Iran Tensions Spark Uptick in Oil Prices Amid Global Market Decline
Investor Takeaway
Investors should consider the potential benefits of Anupam Rasayan's acquisition of Bliss GVS Pharma, including strengthened presence in the pharmaceutical value chain.
More in Market
Treasury Yields Experience Largest Increase in Two Weeks Following Release of Labor Market Data
US-Iran Tensions Spark Uptick in Oil Prices Amid Global Market Decline
Indian Stocks to Watch: BHEL, Agarwal Industrial, JBM Auto, Rajesh Exports, Indian Energy Exchange, Lenskart Solutions in Market Focus on June 4.
